These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21763018)

  • 21. Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome.
    Eggers KM; Lagerqvist B; Venge P; Wallentin L; Lindahl B
    J Am Coll Cardiol; 2009 Jul; 54(4):357-64. PubMed ID: 19608034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of renal function and cardiac biomarkers (NT-proBNP and Troponin) in determining mortality and cardiac outcome in atheromatous renovascular disease.
    Chrysochou C; Manzoor S; Wright J; Roberts SA; Wood G; McDowell G; Kalra PA
    Kidney Blood Press Res; 2009; 32(5):373-9. PubMed ID: 19887825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular biomarkers in chronic kidney disease.
    Park SH; Stenvinkel P; Lindholm B
    J Ren Nutr; 2012 Jan; 22(1):120-7. PubMed ID: 22200428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Developing and assessing cardiovascular biomarkers.
    Dadu RT; Nambi V; Ballantyne CM
    Transl Res; 2012 Apr; 159(4):265-76. PubMed ID: 22424430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating the role of biomarkers for cardiovascular risk prediction: focus on CRP, BNP and urinary microalbumin.
    May A; Wang TJ
    Expert Rev Mol Diagn; 2007 Nov; 7(6):793-804. PubMed ID: 18020909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Role of biomarkers for risk stratification in the prevention of cardiovascular diseases].
    Sinning C; Keller T; Blankenberg S
    Dtsch Med Wochenschr; 2009 Oct; 134(40):2019-22. PubMed ID: 19777420
    [No Abstract]   [Full Text] [Related]  

  • 27. NT-proBNP as a means of triage for the risk of hospitalisation in primary care.
    Adlbrecht C; Neuhold S; Hülsmann M; Strunk G; Ehmsen U; Scholten C; Maurer G; Pacher R
    Eur J Prev Cardiol; 2012 Feb; 19(1):55-61. PubMed ID: 21450621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications.
    Kociol RD; Pang PS; Gheorghiade M; Fonarow GC; O'Connor CM; Felker GM
    J Am Coll Cardiol; 2010 Sep; 56(14):1071-8. PubMed ID: 20863950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New biomarkers for cardiovascular risk evaluation].
    Chironi G
    Rev Prat; 2012 Jun; 62(6):783-5. PubMed ID: 22838270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarkers of cardiovascular damage and dysfunction--an overview.
    Collinson PO; Gaze DC
    Heart Lung Circ; 2007; 16 Suppl 3():S71-82. PubMed ID: 17618829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical usefulness of biomarkers in cardiac failure].
    Paredes C A; Vega J; de León A; Kanacri A; Castro P; Baeza R
    Rev Med Chil; 2013 Dec; 141(12):1560-9. PubMed ID: 24728434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels.
    Tello-Montoliu A; Marín F; Roldán V; Mainar L; López MT; Sogorb F; Vicente V; Lip GY
    J Intern Med; 2007 Dec; 262(6):651-8. PubMed ID: 17986200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B-type natriuretic peptide in heart failure.
    Moe GW
    Curr Opin Cardiol; 2006 May; 21(3):208-14. PubMed ID: 16601459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease.
    Nozaki T; Sugiyama S; Koga H; Sugamura K; Ohba K; Matsuzawa Y; Sumida H; Matsui K; Jinnouchi H; Ogawa H
    J Am Coll Cardiol; 2009 Aug; 54(7):601-8. PubMed ID: 19660689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study.
    Blankenberg S; McQueen MJ; Smieja M; Pogue J; Balion C; Lonn E; Rupprecht HJ; Bickel C; Tiret L; Cambien F; Gerstein H; Münzel T; Yusuf S;
    Circulation; 2006 Jul; 114(3):201-8. PubMed ID: 16831981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biomarkers for cardiovascular disease: challenges and future directions.
    May A; Wang TJ
    Trends Mol Med; 2008 Jun; 14(6):261-7. PubMed ID: 18487087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Usefulness of elevations in serum choline and free F2)-isoprostane to predict 30-day cardiovascular outcomes in patients with acute coronary syndrome.
    LeLeiko RM; Vaccari CS; Sola S; Merchant N; Nagamia SH; Thoenes M; Khan BV
    Am J Cardiol; 2009 Sep; 104(5):638-43. PubMed ID: 19699337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating microRNAs: biomarkers or mediators of cardiovascular diseases?
    Fichtlscherer S; Zeiher AM; Dimmeler S
    Arterioscler Thromb Vasc Biol; 2011 Nov; 31(11):2383-90. PubMed ID: 22011751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel biomarkers in cardiovascular disease: research tools or ready for personalized medicine?
    Stratz C; Amann M; Berg DD; Morrow DA; Neumann FJ; Hochholzer W
    Cardiol Rev; 2012; 20(3):111-7. PubMed ID: 22301714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simultaneous measurement of cardiac troponin I, B-type natriuretic peptide, and C-reactive protein for the prediction of long-term cardiac outcome after cardiac surgery.
    Fellahi JL; Hanouz JL; Le Manach Y; Gué X; Monier E; Guillou L; Riou B
    Anesthesiology; 2009 Aug; 111(2):250-7. PubMed ID: 19568166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.